The Clinical Observation of Inflammation Theory for Depression: The Initiative of the Formosa Long COVID Multicenter Study (FOCuS)

There is growing evidence that the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased risks of psychiatric sequelae. Depression, anxiety, cognitive impairments, sleep disturbance, and fatigue during and after the acute phase of COVID-19 are prevalent, long-lasting, and exerting negative consequences on well-being and imposing a huge burden on healthcare systems and society. This current review presented timely updates of clinical research findings, particularly focusing on the pathogenetic mechanisms underlying the neuropsychiatric sequelae, and identified potential key targets for developing effective treatment strategies for long COVID. In addition, we introduced the Formosa Long COVID Multicenter Study (FOCuS), which aims to apply the inflammation theory to the pathogenesis and the psychosocial and nutrition treatments of post-COVID depression and anxiety.

[1]  K. Su,et al.  Unresolved Systemic Inflammation, Long COVID, and the Common Pathomechanisms of Somatic and Psychiatric Comorbidity , 2022, Journal of clinical medicine.

[2]  M. S. Johnson,et al.  Psychiatric symptoms in COVID-19-positive individuals in the general population: Trajectories of depression, anxiety, and insomnia , 2022, Psychiatry Research.

[3]  F. Benedetti,et al.  Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue , 2022, Journal of Psychiatric Research.

[4]  M. Taquet,et al.  Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients , 2022, The Lancet Psychiatry.

[5]  A. Al-Harrasi,et al.  Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches , 2022, Biomolecules.

[6]  K. Bhaskaran,et al.  Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records , 2022, Nature Communications.

[7]  F. Benedetti,et al.  Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment , 2022, CNS Drugs.

[8]  Shaghayegh Haghjooy Javanmard,et al.  A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021 , 2022, medRxiv.

[9]  M. Covasa,et al.  Do Diet and Dietary Supplements Mitigate Clinical Outcomes in COVID-19? , 2022, Nutrients.

[10]  Long Khanh-Dao Le,et al.  Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan , 2022, BMC Public Health.

[11]  K. Miskowiak,et al.  Trajectory of cognitive impairments over 1 year after COVID‐19 hospitalisation: Pattern, severity, and functional implications , 2022, European Neuropsychopharmacology.

[12]  C. Pariante,et al.  Long COVID and long chain fatty acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19 , 2022, Brain, Behavior, and Immunity.

[13]  A. Steptoe,et al.  Long-term psychological consequences of long Covid: a propensity score matching analysis comparing trajectories of depression and anxiety symptoms before and after contracting long Covid vs short Covid , 2022, medRxiv.

[14]  Z. Bhat,et al.  Delving the role of nutritional psychiatry to mitigate the COVID-19 pandemic induced stress, anxiety and depression , 2022, Trends in Food Science & Technology.

[15]  Nelson B Rodrigues,et al.  Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis , 2021, Brain, Behavior, and Immunity.

[16]  B. Carter,et al.  Long-term effects of COVID-19 on mental health: A systematic review , 2021, Journal of Affective Disorders.

[17]  Janet Diaz,et al.  A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.

[18]  C. Pariante Increased Inflammation in Depression: A Little in All, or a Lot in a Few? , 2021, The American journal of psychiatry.

[19]  F. Limosin,et al.  Do Anxiety and Depression Predict Persistent Physical Symptoms After a Severe COVID-19 Episode? A Prospective Study , 2021, Frontiers in Psychiatry.

[20]  A. Toubasi,et al.  Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors , 2021, International journal of psychiatry in clinical practice.

[21]  Reed J. D. Sorensen,et al.  Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic , 2021, The Lancet.

[22]  C. Correll,et al.  Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A) , 2021, Journal of Affective Disorders.

[23]  U. Merle,et al.  Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Correll,et al.  The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic , 2021, Journal of Affective Disorders.

[25]  P. Brambilla,et al.  Neuroinflammation in Major Depressive Disorder: A Review of PET Imaging Studies Examining the 18-kDa Translocator Protein. , 2021, Journal of affective disorders.

[26]  Lauren E. Oberlin,et al.  A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment , 2021, Current opinion in psychiatry.

[27]  T. Penzel,et al.  Brain Mechanisms of COVID-19-Sleep Disorders , 2021, International journal of molecular sciences.

[28]  E. Vieta,et al.  Mind long COVID: Psychiatric sequelae of SARS-CoV-2 infection , 2021, European Neuropsychopharmacology.

[29]  M. Maes,et al.  A Review of the Global Impact of the COVID-19 Pandemic on Public Mental Health, with a Comparison Between the USA, Australia, and Poland with Taiwan and Thailand , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[30]  M. Boldrini,et al.  How COVID-19 Affects the Brain. , 2021, JAMA psychiatry.

[31]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[32]  L. Bairy,et al.  LONG TERM COMPLICATIONS OF COVID-19 , 2021, International Journal of Medical and Biomedical Studies.

[33]  F. Benedetti,et al.  Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up , 2021, Brain, Behavior, and Immunity.

[34]  C. Pariante,et al.  The three frontlines against COVID-19: Brain, Behavior, and Immunity , 2021, Brain, Behavior, and Immunity.

[35]  A. Morice,et al.  Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? , 2021, Lung.

[36]  B. Penninx,et al.  Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts , 2021, Molecular Psychiatry.

[37]  M. Sojka,et al.  SARS-CoV-2 RNA in the Cerebrospinal Fluid of a Patient with Long COVID , 2021, Therapeutic advances in infectious disease.

[38]  R. Marioni,et al.  Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder , 2020, Brain, Behavior, and Immunity.

[39]  Paul J. Harrison,et al.  Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA , 2020, The Lancet Psychiatry.

[40]  M. Ota,et al.  Cerebrospinal Fluid Inflammatory Cytokine Levels in Patients With Major Psychiatric Disorders: A Multiplex Immunoassay Study , 2021, Frontiers in Pharmacology.

[41]  M. Sivan,et al.  NICE guideline on long covid , 2020, BMJ.

[42]  C. Pariante,et al.  Omega-3 fatty acids in the psychological and physiological resilience against COVID-19 , 2020, Prostaglandins, Leukotrienes and Essential Fatty Acids.

[43]  S. Hollon,et al.  Mental health and clinical psychological science in the time of COVID-19: Challenges, opportunities, and a call to action. , 2020, The American psychologist.

[44]  C. Nemeroff,et al.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble , 2020, Neuron.

[45]  G. Shields,et al.  Psychosocial Interventions and Immune System Function: A Systematic Review and Meta-analysis of Randomized Clinical Trials. , 2020, JAMA psychiatry.

[46]  Tedros Adhanom Ghebreyesus Addressing mental health needs: an integral part of COVID‐19 response , 2020, World psychiatry : official journal of the World Psychiatric Association.

[47]  Alex Brito,et al.  Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis , 2020, Nutrients.

[48]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[49]  M. Rotondi,et al.  The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system , 2020, Cytokine & Growth Factor Reviews.

[50]  Guiqiang Wang,et al.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality , 2020, International Journal of Antimicrobial Agents.

[51]  Sung-Wan Kim,et al.  Using psychoneuroimmunity against COVID-19 , 2020, Brain, Behavior, and Immunity.

[52]  O. Howes,et al.  Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls , 2020, Brain, Behavior, and Immunity.

[53]  Suxin Wan,et al.  Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.

[54]  C. Pariante,et al.  Is there neuroinflammation in depression? Understanding the link between the brain and the peripheral immune system in depression. , 2020, International review of neurobiology.

[55]  M. Maes,et al.  International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder , 2019, Psychotherapy and Psychosomatics.

[56]  F. Giuliani,et al.  The Role of Inflammation in Depression and Fatigue , 2019, Front. Immunol..

[57]  Peter B. Jones,et al.  Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels , 2019, Psychological Medicine.

[58]  K. Hashimoto,et al.  The Efficacy of Omega-3 Fatty Acids for Depressive Symptoms among Pregnant Women in Japan and Taiwan: A Randomized, Double-Blind, Placebo-Controlled Trial (SYNCHRO; NCT01948596) , 2018, Psychotherapy and Psychosomatics.

[59]  M. Craske,et al.  The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation , 2018, Neuroscience & Biobehavioral Reviews.

[60]  Y. Matsuoka,et al.  Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms , 2018, JAMA network open.

[61]  George M. Slavich,et al.  Mindfulness meditation and the immune system: a systematic review of randomized controlled trials , 2016, Annals of the New York Academy of Sciences.

[62]  M. Irwin,et al.  Mind–body therapies and control of inflammatory biology: A descriptive review , 2016, Brain, Behavior, and Immunity.

[63]  Andrew H. Miller,et al.  The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.

[64]  Michael R. Irwin,et al.  The Effects of Mind-Body Therapies on the Immune System: Meta-Analysis , 2014, PloS one.

[65]  M. Irwin,et al.  From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. , 2014, Psychological bulletin.

[66]  Qiu-qin Han,et al.  Inflammation: a mechanism of depression? , 2014, Neuroscience Bulletin.

[67]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[68]  K. Su,et al.  A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. , 2007, The Journal of clinical psychiatry.

[69]  Shih-Yi Huang,et al.  Omega-3 polyunsaturated fatty acids for postpartum depression. , 2004, American journal of obstetrics and gynecology.